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Summary We examined the reactivity of four p53-specific monoclonal antibodies - PAb 1801, p53-BP-12,
D07 and CMI - on sections of formalin-fixed tissue collected from 245 breast carcinomas. Immunodetection
of p53 varied between 37.6% and 46.6%. The greatest variation was observed among lobular carcinomas and
low-grade tumours in which immunodetection varied between 8.3% and 27.3%. In contrast, immunodetection
of p53 in invasive ductal carcinomas was subject to a lower degree of variability with between 40.6% and
49.7% of these tumours proving to be positive. In general, we found antibodies PAb 1801 and D07 to be the
most effective in immunolocalising p53. Immunodetection of p53 with each of the four antibodies was found
to correlate strongly with tumour grade. In survival analysis, the results gained using antibody PAb 1801
proved to be of greatest statistical significance and to provide the strongest index of prognosis. A significant
relationship was observed between immunodetection of p53 with each of the four antibodies and poor
responsiveness to endocrine therapy. In addition, relationships were also observed between p53 immunostain-
ing and tumour oestrogen receptor (ER) status as well as c-jun expression. We observed no correlation
between abnormalities of the p53 and the Rb gene products or between elevated c-erbB-2 or epidermal growth
factor receptor (EGFR) expression and immunodetection of p53.
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Prediction of likely outcome in breast cancer has acquired
greater importance following the demonstration by meta-
analysis that chemotherapy provides enhanced 10 year sur-
vival rates (Early Breast Cancer Trials Collaborative Group,
1992). Accurate prediction of outcome would allow rational
allocation of patients to appropriate treatment regimens.
Lymph node status is accepted as a primary prognostic
factor but it is recognised that greater predictive power
would be desirable, and numerous potential prognostic fac-
tors have been examined, for example tumour grade, hor-
mone receptor status and c-erb-B2 protein expression.
(Barnes et al., 1989; Neville et al., 1990; Galea et al., 1992).
Cattoretti et al. (1988) were the first to demonstrate that p53
gene expression might serve as a prognostic indicator in
breast cancer. This has subsequently been confirmed by other
workers who have shown that p53 protein overexpression
determined by immunohistochemistry gives significant supp-
lementary information regarding likely outcome (Iwaya et al.,
1991; Sawan et al., 1992; Barnes et al., 1993; Yamashita et
al., 1993).
The p53 gene is located on the short arm of chromosome
17 and it encodes a 53 kDa nuclear phosphoprotein involved
in the control of cell proliferation (Baker et al., 1989). The
exact function of the p53 protein is not fully understood but
it may play a role in DNA replication and regulation of
transcription (Levine et al., 1991). Recent studies have shown
that p53 in its 'wild' form may act as a tumour-suppressor
gene (Lane and Benchimol, 1990). The precise mechanism of
p53 tumour suppression is not known. Recent evidence sug-
gests that p53 indirectly inhibits cell proliferation by
regulating the transcription of other unidentified genes (Kern
et al., 1992). The p53 gene has been found mutated and/or
deleted in a wide range of tumours (Mulligan et al., 1990;
Levine et at., 1991). Functional inactivation of the p53 gene
by mutation or allelic loss appears to be one of the com-
monest genetic abnormalities in human cancer (Lane, 1992).
Structural abnormalities of the p53 gene have been detected
in sarcomas, leukaemias, colonic, lung, oesophageal apd liver
carcinomas (Vogelstein and Kinzler, 1992). Mutation leads to
altered protein conformation and increased half-life of the
p53 gene product, resulting in detectability by immunohisto-
chemistry. Recent immunohistochemical studies have shown
that the detection rate of mutated p53 protein in breast
cancer ranges between 13% and 53.5% (Cattoretti et al.,
1988; Sawan et al., 1992; Martinazzi et al., 1993; Yamashita
et al., 1993).
The aim of the present study was to assess the expression
of the p53 gene in a large series of routinely processed
human breast carcinomas and its relation to tumour
variables, prognostic factors and patient outcome. In doing
so we compared the effectiveness of four different antibodies
commonly used in immunolocalisation studies of p53.
Materials and methods
Tissues
Our study included 245 resected breast carcinomas from 245
female patients (mean age: 57.02 years with a standard devia-
tion of 13.87, range: 24-98 years) attending the Royal Vic-
toria Infirmary, Newcastle upon Tyne, UK between 1983 and
1990. Tumour tissues were received fresh in the Department
of Pathology, were dissected and block-sized pieces were
fixed overnight in neutral buffered formalin. Following
primary fixation the blocks were further trimmed and post-
fixed in formal sublimate (saturated aqueous mercuric
chloride and 37% formaldehyde, 9: 1) for approximately 3 h.
Blocks were then routinely paraffin embedded. The his-
tological classification of the tumours was based on the
WHO criteria and the grading was according to the criteria
of Bloom and Richardson modified by Elston (Elston and
Ellis, 1991). The histological diagnosis, tumour size and
lymph node status was determined during routine
pathological assessment. Tumour grade was determined by
one observer.
Patients were followed up for a maximum of 103 months.
The mean follow-up time was 39 months. Patient follow-up
data were acquired by reference to the case notes. Relapse-
free and overall (time to death) survival were measured from
the date of surgery. Only deaths due to breast cancer were
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considered for the purposes of the study. Patients dying of
causes other than breast cancer were censored at the end of
their observation times. Relapse was considered as any
evidence of metastasis or local recurrence.
The patient group has been the subject of other prognostic
studies. Data concerning oestrogen receptor (ER), pro-
gesterone receptor (PgR) and epidermal growth factor recep-
tor (EGFR) status determined by frozen section immunohis-
tochemistry (Elston and Ellis. 1991; Piggott et al., 1991;
Sawan et al., 1992), expression of c-erbB-2 and c-jun onco-
proteins and expression of Rb protein determined by paraffin
section immunochemistry were available (Corbett et al., 1990;
Anderson et al., 1994; Tiniakos et al., 1994). In addition, a
small subgroup of patients (n = 17) has been previously
assessed regarding response to endocrine therapy on relapse,
and these data were also available for comparative studies.
The minimum criterion for response to hormonal therapy on
relapse was disease that did not progress for at least 6
months (Henry et al., 1991).
Immunohistochemical method and antibodies
The streptavidin-biotin complex (sABC) (Dakopatts, Den-
mark) immunoperoxidase techique was used on 5-gm-thick
paraffin sections. Table 1 displays in detail the four
antibodies used for the detection of p53 protein. The
antibodies used were selected on the basis of reactivity with
paraffin-embedded tissue and at the time were the only
reagents effective for this application. The ideal immunos-
taining conditions for each of the antibodies had been estab-
lished in preliminary experiments. The microwave antigen
retrieval technique preceded immunohistochemical staining
using DO7 and PAb 1801 monoclonal anti-p53 antibodies
(Shi et al., 1991). Briefly, the tissue sections were placed in
sodium citrate solution (0.01 M, pH 6.0) and then incubated
twice for 5 min in an 800 W microwave oven. The
chromogen of choice was diaminobenzidine (DAB).
Positive controls consisted of breast cancer sections with
known detectable p53 protein. In each case, a section in
which the primary antibody incubation was omitted was used
as a negative control.
Scoring
The cellular immunoreaction was scored on the basis of the
intensity of the specific nuclear staining on a five-point scale:
0, no staining; 1, equivocal or very weak staining; 2, definite
staining of moderate intensity; 3, strong staining; 4, very
strong staining. Only tumours scoring 2 or more were
regarded as 'positive'. The proportion of cells staining was
not taken into account. Some tumours showed occasional
isolated individual cells with strong nuclear staining. These
were regarded as probable apoptotic cells and discounted.
The immunoreaction was assessed independently by two his-
topathologists.
Statistical analysis
The chi-squared test, together when appropriate with Yeat's
correction, was used for the correlations between the different
tumour and patient variables. Log-rank tests were used for
survivial analyses. All analyses were carried out using Solo
Statistical Software (BMDP Statistical Software, USA).
Table I Antibodies specific to p53 protein
Antibody Soource Species Dilution Incubation
DO7b Novocastra M 1:100 16h, 4°C
PAbI8OlC Novocastra M 1:40 a16h, 4°C
p53-BP-12d Novocastra M 1:50 1 h, 25°C
CMIe Novocastra P 1:200 16 h, 4°C
aMicrowave antigen retrieval. M, mouse monoclonal antibody; P,
rabbit polyclonal antiserum. bBartek et al. (1993). cBanks et al.
(1986). dBArtek et al. (1991). eVojtesek et al. (1992).
Results
The apparent rate of p53 protein overexpression/stabilisation
in breast carcinomas varied from 37.6% to 46.6% depending
on the anti-p53 antibody used (Table II, Figure 1). The
highest proportion of cases showing nuclear p53 immuno-
staining was detected using the antibody PAb 1801, while the
lowest number of p53-positive cases was observed using the
polyclonal antibody CM1. The nuclear immunostaining pro-
duced using CM1 was often accompanied by the presence of
cytoplasmic reactivity and non-specific background staining.
In addition, in several instances using CM 1, cytoplasmic
reactivity was observed in the absence of nuclear staining
despite the fact that positive nuclear reactivity was produced
by each of the other antibodies. In subgroups stratified by
histological type, the rate of p53 protein immunodetection
varied from 40.6% to 49.7% in invasive ductal carcinomas
(IDCs) (n = 205) and 8.3% to 27.3% in invasive lobular
carcinomas (classical type) (ILCs) (n = 15). Colloid car-
cinomas (n = 7), with the exception of one case, were p53
negative with all the antibodies used. One out of three
medullary carcinomas and one out of five in situ ductal
carcinomas showed positive p53 immunoreactivity, as
detected with all four antibodies. One tubular and one
squamous carcinoma included in the study were p53
negative.
As expected a very strong and highly significant correlation
for positive staining with any of the four p53 antibodies was
observed with each of the others. However, in each cross-
tabulation analysis a number of cases with discrepant stain-
ing results were observed i.e. scored p53 positive with one
antibody and negative with another, or vice versa. The
strongest correlation of scoring results was observed for D07
compared with PAb 1801; by contrast when CM1 and p53-
BP-12 were compared, 23% of cases were discordant. Fifty-
seven out of 245 cases (23.2%) were concordant for positive
staining for all four antibodies, while 89/245 (36.3%) were
negative for all four; this leaves a pool of 41.5% cases in
which some degree of discordancy is observed.
Lymph node status was the most powerful predictive fac-
tor for both time to relapse and time to death (P = 0.021 and
P = 0.0001 respectively). Using the monoclonal antibody
PAb 1801, p53 expression was associated with poorer overall
survival when all patients were considered (P = 0.017); in
subgroups stratified by node status this observation was sus-
tained only in the node-negative group (P = 0.037) (Figure
2). When relapse-free survival was assessed, immunostaining
for p53 using PAb 1801 was not associated with poorer
prognosis. Immunostaining for p53 protein did not relate
significantly to survival or relapse-free survival, using D07,
p53-BP-12 and CM1 antibodies. When groups of patients
were defined according to positivity for any antibody, com-
pared with negativity for all antibodies, no survival
differences for either of these groups was observed, either
taking the data as a whole, or by stratification according to
node status.
Using each one of the four antibodies, p53 expression
correlated positively with higher tumour grade (P = 0.0014,
PAb 1801; P = 0.0004, p53-BP-12; P = 0.0012, D07; P =
0.0249, CM1) (Figure 3). Staining using D07 correlated
significantly with negative ER status, as determined with the
anti-ER monoclonal antibody ERLH1 (Henry et al., 1993);
in general p53-negative breast carcinomas were more fre-
Table II p53 protein immunoreactivity in routinely processed breast
carcinoma
Antibody No. of positive cases Percentage
PAb 1801 111/238 46.6
p53-BP-12 100/232 43.0
D07 98/245 40.0
CMI 91/242 37.6p53 protein in breast carcinoma
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Figure 1 Invasive ductal carcinoma showing intense nuclear immunopositivity for p53 using D07 (a) and PAb 1801 (b). Weaker
p53 immunostaining is observed with p53-BP-12 (c). Note cytoplasmic and background staining using CMI (d).
quently ER positive (P = 0.028) (Figure 4). Subsequent
examination of the relationship between response to endo-
crine therapy on relapse and p53 status indicated that
positive nuclear immunostaining was correlated inversely
with response (chi-square values with Yates' correction: PAb
1801, X2 = 4.129; p53-BP-12, x2 = 4.178, D07, x2 = 5.727;
CM1, % = 4.129) (Figure 5). Thus in each instance this
relationship proved statistically significant (PAb 1801
P=0.00064; p53-BP-12 P=0.00069; D07 P=0.00516;
CM1 P = 0.00064). Although the number of patients within
this group was small, incorporating only 17 patients, it was
notable that no p53-positive individual showed a response to
endocrine therapy.
Using the antibody PAb 1801, our results also suggested a
relationship between tumour p53 immunostaining and c-jun
(P = 0.0307). Our data indicated that although most tumours
appeared to express c-jun, approximately two-thirds of this
group were found to be p53 negative, while in contrast
three-quarters of the c-jun-negative tumours were found to
be p53 positive. As a result, p53-negative tumours were
found to be approximately five times more likely to be c-jun
positive than p53-positive tumours. Finally, no significant
relationship was observed between p53 expression and c-
erbB-2 oncoprotein, retinoblastoma gene protein, EGFR and
progesterone receptor expression.
Discussion
Abnormalities in the p53 gene, either in the form of gene loss
or in the form of mutations, are the most common genetic
abnormality in primary breast carcinoma (Varley et al.,
1991). The human p53 gene has been mapped on the short
arm of chromosome 17, where other genes with prognostic
significance in breast cancer, such as c-erbB-2 and the anti-
metastatic gene nm23, are also located (Sawan et al., 1994).
Our study compared one polyclonal and three monoclonal
antibodies, which have often been used previously, in isola-
tion, in immunohistochemical studies that have sought to
define tumour p53 status. We sought to gain a consensus by
applying each of these antibodies in parallel to study p53
expression/stabilisation within a large series of breast car-
cinomas. The three monoclonal antibodies employed in this
comparison, namely D07, PAb 1801 and p53-BP-12, are
each known to react with the amino-terminal portion of the
p53 molecule, which is distal to the central region, which is
most frequently affected by point mutations. Thus, we would
expect a high degree of structual conservation within the
N-terminal region reactive with these antibodies. Although
each of the monoclonal antibodies recognises the
immunodominant N-terminal portion of the p53 molecule,
the precise location of their complementary epitopes varies
between two sites. Antibody PAb 1801 is known to recognise
an epitope mapping between amino acid residues 32 and 79
(Banks et al., 1986) while antibodies BP-53-12 and D07 react
with the same epitope within the region defined by amino
acids 20-25 (Stephen et al., 1995). In addition, this N-
terminal sequence of amino acids is also known to overlap
with a seven amino acid sequence (18-23), that constitutes
the binding site for the p53 modulatory protein MDM2
(Picksley et al., 1994).
In the present study, the detection rate of p53 protein in
breast carcinoma varied from 37.6% to 46.6%, depending on
the anti-p53 antibody used. These results are in keeping with
the findings of previous similar studies (Cattoretti et al.,
1988; Walker et al., 1991; Barbareshi et al., 1992; Poller et
al., 1992; Sawan et al., 1992; Yamashita et al., 1993). How-
ever, in other studies the rate of p53-positive breast car-
cinomas was found to be lower (13-23%) (Iwaya et al.,
1991; Spandidos et al., 1992; Trudel et al., 1992; Martinazzi
a
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This study has firstly confirmed the prognostic significance
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Figure 2 Patient survival related to tumour p53 protein expres-
sion determined bv immunohistochemistry using the monoclonal
antibody PAb 1801. (a) All patients. (b) lymph node-negative
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(PAbl801, D07, p53-BP-12 and CMI), PAb 1801 and to a
lesser extent D07 proved to be the most effective antibodies
for the immunodetection of p53 protein in routinely pro-
cessed material, confirming the results of similar studies in
colonic and cervical carcinomas (Baas et al., 1994; Lambkin
et al., 1994). Diminished performance of p53-BP-12 relative
to 1801 and D07 could reflect the use of this antibody
without associated antigen retrieval. Although preliminary
experiments, which optimised the staining conditions for each
antibody, indicated that microwave pretreatment of sections
enhanced the background cytoplasmic staining produced by
p53-BP-12. This effect was not apparent with PAb 1801 or
D07. We have further demonstrated that in this particular
series of tumours the p53 immunohistochemical status, as
detected by PAb 1801, gives the most significant information
with respect to the survival of all patients and of the node-
negative subgroup, which presents the greatest dilemma for
design of treatment strategies. This finding supports the
observation made by Allred et al. (1993) in their study of p53
expression in frozen sections of breast tumour tissue from
node-negative patients. The degree of separation of the cur-
vival curves in our study group, however, is not as great as
had been observed by previous workers (Elledge et al., 1993);
and in our previous smaller studies using frozen section
(Ostrowski et al., 1991) and paraffin section immunohis-
tochemistry (Sawan et al., 1992); the reasons for this are not
clear.
There are a number of different possible explanations for
differing performances between antibodies in terms of predic-
tive power. One possibility is the sensitivity of the detection
system, it is notable that the monoclonal antibody detecting
the greatest number of cases positive for p53 exhibits the
greatest prognostic power. In general, good correspondence,
was observed between the results obtained with D07 and
p53-BP-12 but additional positive cases were recorded using
PAb 1801. Whether this difference relates directly to the
different epitopes recognised by D07/p53-BP-12 and PAb
1801 or is a function of antibody avidity and minimum
thresholds of detection or even a reflection of reactivity of
our detector with different p53 antibody subclasses, cannot
be categorically defined from this work. It is also possible
that the differences between the antibodies reflect the sugges-
tion that p53 may be present in different tumours in different
molecular forms and evidence for this is presented by Span-
dau (1994), who showed differing patterns of wild-type p53 in
the normal epidermis, depending upon the antibody used for
immunostaining. Furthermore, differing antibody detection
p53 protein in breast carcinoma
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rates could be related to masking of epitopes as a result of
p53 binding to other proteins, although it is likely that
fixation together with microwave antigen retrieval would
eliminate this effect. However, it is interesting to note that
each of the monoclonal antibodies reactive with amino acid
sequence 20-25 detected fewer positive tumours than the
antibody of choice PAb 1801. It is tempting to speculate that
this region is more subject to alteration during fixation or
complex formation, which may interfere with subsequent
reaction of the antibody with its complementary ligand. The
polyclonal antibody CM1 proved the least effective antibody
in immunolocalising p53. In multiple instances cytoplasmic
staining was evident with CM1 in the complete absence of
nuclear staining, although each of the monoclonal antibodies
produced defined nuclear staining on sections from the same
tumour. Equally, a number of tumours scored negative by
p53 in immunohistochemistry have been found to express
significant levels of p53, which may be detected using quan-
titative non-competitive ELISAs that employed CM1 as the
detector (Thomas et al., 1995). This indicates that CM1 may
exhibit reduced sensitivity for p53, and may be more subject
to fixation artifacts in immunohistochemistry than any of the
three monoclonal antibodies studied. Furthermore, this work
has reinforced our findings in respect of differential efficiency
of p53 detection using antibodies PAb 1801, DO7 and CM1
to detect p53 in frozen, unfixed tissue sections in direct
comparison with p53 levels assessed by ELISA in cytosols
prepared from the same tissue.
It has been previously shown that the presence of detec-
table p53 protein in breast cancer is significantly correlated
with poor tumour differentiation and poor patient prognosis
(Iwaya et al., 1991; Sawan et al., 1992; Spandidos et al.,
1992; Yamashita et al., 1993). It might be proposed that the
association of p53 immunostaining with prognosis would
reflect its correlation with tumour grade. In this study
immunostaining for any of the four antibodies correlated
strongly with grade but only PAb 1801 shows significant
survival effects. This suggests an effect independent of grade,
but we could detect no prognostic effects for p53 in any
group stratified for grade, using any antibody.
Previous studies have shown that the presence of detec-
table p53 protein in breast cancer is significantly correlated
with increased levels of c-erbB-2 oncoprotein (Iwaya et al.,
1991; Barbareschi et al., 1992; Poller et al., 1992; Spandidos
et al., 1992; Martinazzi et al., 1993), and EGFR (Walker et
al., 1991; Poller et al., 1992), but similar correlations were
not observed in our material. Correlation between Rb and
p53 structural abnormalities has been reported in breast car-
cinoma and in several other malignant tumours (Hall and
Lane, 1994). In our study and in others, no correlation was
found between the expression of Rb and p53 genes at the
cellular level. (Walker et al., 1991; Trudel et al., 1992).
However, within this same series of tumours a significant
relationship was observed between expression of Rb and
cyclin Dl (McIntosh et al., 1995). An interesting finding
reported in the current study for the first time, was the
significant correlation of the immunolocalisation of p53 pro-
tein with the apparent absence of c-jun oncoprotein in the
breast cancer cells.
Of great interest is our observation that p53 overexpression
(as determined by any of the four antibodies), is associated
with patients' failure to respond to endocrine therapy. While
it is true that p53-positive tumours tend to be negative for
ER and to be of high grade, this observation clearly requires
further investigation since our numbers are small. Currently
cases assembled from the Northern Region hospitals are
being examined in order to enable us to more fully test this
relation. The possibility that p53 immunostaining can pro-
vide objective supplementary predictive information for
endocrine response is an attractive one.
A further contentious issue regarding p53 protein overexp-
ression concerns the relationship to p53 mutation. It is now
well established that although mutation and overexpression
are correlated (Baas et al., 1994), a high degree of discor-
dance is observed (Jacquemier et al., 1994; Xu et al., 1994).
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Immunodetection of p53 protein has been recently reported
in normal cells following genotoxic injury, which leads to
stabilisation of the wild-type p53 (MacKay et al., 1988). The
evaluation of the results of the immunohistochemical detec-
tion of p53 protein, should be carried out with great care
since the observed tumour immunophenotypes do not always
reflect the underlying biochemical and biological cellular
changes. It will clearly be of importance to compare the
prognostic significance of mutation per se to overexpression
determined by immunostaining and this is now proceeding in
our laboratory. In addition, since we have demonstrated the
differing prognostic significance of p53 determined by various
antibodies, it will now be important to investigate the
significance of the relationship between such staining
differences (perhaps reflecting different molecular forms),
specific mutations and survival.
It is clear that in the study of p53 alterations in human
tumours, it is no longer sufficient to designate cases as 'p53
positive'. Rather, the molecular change must be carefully
defined by the antibody used for immunohistochemistry or
by DNA analysis for mutation, and ideally both. In addition,
assessment of expression of DNA binding proteins such as
MDM2 may be important.
This study demonstrates that the relationship of p53 over
expression to clinical outcome is complex, and that more
comprehensive analysis is required to translate the results
into reliable clinical guidelines.
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